Pfizer, Roche Join $14.6M Financing for Mass Cytometry Startup DVS Sciences
July 15, 2011
Pfizer, Roche Join $14.6M Financing for Mass Cytometry Startup DVS Sciences
According to founder and CEO Scott Tanner, the funds will go primarily toward ramping up production of CyTOF instruments, reagent production, and the establishment of a global sales and service team.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Stanford Team Uses DVS Sciences' CyTOF for Massive Hematopoietic Cell Protein Signaling Project
May 13, 2011 / ProteoMonitor - Q&A: University of Toronto's Scott Tanner on the Use of Atomic Mass Spectrometry in Proteomics
March 4, 2011 / ProteoMonitor - Stanford Researchers Applying Multi-omics Approach to Profiling Immune Health
April 26, 2013 / ProteoMonitor - Nolan Lab Profiles Small-Molecule Inhibitors Using New Multiplexing Method for DVS Sciences' CyTOF
August 24, 2012 / ProteoMonitor - DVS Sciences Collaborating with Cytobank on Informatics Tools for CyTOF Platform
June 29, 2012 / ProteoMonitor